Illumina (NASDAQ:ILMN) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Illumina (NASDAQ:ILMN) in a research note issued on Sunday. The firm set a “buy” rating on the life sciences company’s stock.

A number of other equities research analysts have also weighed in on the stock. Barclays raised their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Scotiabank lowered their price target on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a report on Monday, May 6th. Jefferies Financial Group started coverage on shares of Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective for the company. Stephens reissued an “overweight” rating and set a $170.00 price objective on shares of Illumina in a report on Tuesday, May 7th. Finally, Robert W. Baird raised their price objective on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $157.62.

Illumina Price Performance

Illumina stock opened at $105.50 on Friday. Illumina has a 52-week low of $89.00 and a 52-week high of $195.64. The firm has a fifty day moving average of $111.62 and a 200-day moving average of $127.32. The firm has a market capitalization of $16.81 billion, a P/E ratio of -12.94 and a beta of 1.20. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business’s revenue was down 1.0% on a year-over-year basis. During the same period last year, the business earned $0.08 EPS. As a group, analysts predict that Illumina will post 0.98 EPS for the current year.

Institutional Trading of Illumina

Several hedge funds have recently bought and sold shares of the company. Bouvel Investment Partners LLC lifted its position in Illumina by 1.3% in the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after purchasing an additional 84 shares during the last quarter. STF Management LP lifted its position in Illumina by 3.5% in the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after purchasing an additional 90 shares during the last quarter. Global Retirement Partners LLC lifted its position in Illumina by 12.3% in the 1st quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock valued at $118,000 after purchasing an additional 94 shares during the last quarter. Gulf International Bank UK Ltd lifted its position in Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after purchasing an additional 98 shares during the last quarter. Finally, Clear Creek Financial Management LLC lifted its position in Illumina by 6.3% in the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after purchasing an additional 100 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.